Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis

Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion–Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study

(2020) David P. Steensma et al.   JOURNAL OF CLINICAL ONCOLOGY

Survival outcomes in myelofibrosis patients treated with ruxolitinib: A population‐based cohort study in Sweden and Norway

(2019) Frida Schain et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis

(2019) Francesca Palandri et al.   CANCER

Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients

(2018) Francesca Palandri et al.   LEUKEMIA RESEARCH

Imetelstat, a telomerase inhibitor, differentially affects normal and malignant megakaryopoiesis

(2017) G Mosoyan et al.   LEUKEMIA

Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients

(2016) Paola Guglielmelli et al.   AMERICAN JOURNAL OF HEMATOLOGY

A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis

(2015) Ayalew Tefferi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia

(2015) Gabriela M. Baerlocher et al.   NEW ENGLAND JOURNAL OF MEDICINE

How I treat myelofibrosis

(2014) F. Cervantes   BLOOD

Revised assessment of response and long-term discontinuation rates among 111 patients with myelofibrosis treated with momelotinib or ruxolitinib

(2014) R A Abdelrahman et al.   LEUKEMIA

Evaluating the serial use of the myelofibrosis symptom assessment form for measuring symptomatic improvement

(2011) Ruben A. Mesa et al.   CANCER

DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status

(2010) Naseema Gangat et al.   JOURNAL OF CLINICAL ONCOLOGY

Telomere length is severely and similarly reduced in JAK2V617F-positive and -negative myeloproliferative neoplasms

(2008) L Bernard et al.   LEUKEMIA